Cargando…

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration

Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We conducted a multi-center retrospective study of patients with Hodgkin transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephens, Deborah M., Boucher, Ken, Kander, Elizabeth, Parikh, Sameer A., Parry, Erin M., Shadman, Mazyar, Pagel, John M., Cooperrider, Jennifer, Rhodes, Joanna, Mato, Anthony, Winter, Allison, Hill, Brian, Gaballa, Sameh, Danilov, Alexey, Phillips, Tycel, Brander, Danielle M., Smith, Sonali M., Davids, Matthew S., Rogers, Kerry, Glenn, Martha J., Byrd, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561295/ https://www.ncbi.nlm.nih.gov/pubmed/33054118 http://dx.doi.org/10.3324/haematol.2020.256388

Ejemplares similares

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Woyach, Jennifer, et al.
Publicado: (2023)

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
por: Rossi, Davide, et al.
Publicado: (2020)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Childhood trauma fatality and resource allocation in injury control programs in a developing country
por: Roudsari, Bahman S, et al.
Publicado: (2006)

The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease
por: Rhoades, Ruben, et al.
Publicado: (2017)

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
por: Allan, John N., et al.
Publicado: (2021)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
por: Danilov, Alexey V., et al.
Publicado: (2019)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
por: Tam, Constantine, et al.
Publicado: (2023)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
por: Shadman, Mazyar, et al.
Publicado: (2023)

Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
por: Orozco, Johnnie J., et al.
Publicado: (2014)

Dynamic Effects Arise Due to Consumers’ Preferences Depending on Past Choices
por: Askar, Sameh S., et al.
Publicado: (2020)

Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship
por: McPartland, John M.
Publicado: (2009)

Glomangiosarcoma Arising from a Prior Biopsy Site
por: Maselli, Amy M., et al.
Publicado: (2017)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021)

The Value of Leucocyte Examination in Suppurative Conditions Arising from Middle-Ear Infection
por: Darling, John M.
Publicado: (1908)

Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
por: Brander, Danielle M, et al.
Publicado: (2012)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Conversations worth having: using appreciative inquiry to fuel productive and meaningful engagement
por: Stavros, Jacqueline M, et al.
Publicado: (2018)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
por: Rhodes, Joanna M, et al.
Publicado: (2021)

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
por: Mato, Anthony R., et al.
Publicado: (2019)

Primary Cutaneous Melanoma Arising in a Long-Standing Irradiated Keloid
por: Fish, Lindsay M., et al.
Publicado: (2012)

Clear Cell Myoepithelial Carcinoma Arising from the Hard Palate with Metastasis to the Lungs
por: Fang, Jiayun, et al.
Publicado: (2019)

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
por: Shouse, Geoffrey, et al.
Publicado: (2023)

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial
por: Burke, John M, et al.
Publicado: (2023)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

On conditional expectations arising from group actions
por: Frank, M, et al.
Publicado: (1996)

Sweet's Syndrome Arising in a Scar
por: Chern, Casey M., et al.
Publicado: (2017)

Number Concepts without Number Lines in an Indigenous Group of Papua New Guinea
por: Núñez, Rafael, et al.
Publicado: (2012)

Correction: Number Concepts without Number Lines in an Indigenous Group of Papua New Guinea
por: Núñez, Rafael, et al.
Publicado: (2013)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

Osteogenic sarcoma of the breast arising in a cystosarcoma phyllodes: a case report and review of the literature
por: Singhal, Vinay, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_75u39buo402jn1a2agd4v11gdg